CD8A and neoplasm: The efficacy of tumor immunotherapy is restricted by tumor cells evading host immune system surveillance and downregulating the function of immune cells, especially antitumor effector cells, including CD8+ T and CD4+ T cells, natural killer cells (NK), and dendritic cells (DCs) (52, 53).